MYP_014866
Basic Information
Ecallantide
Immunology Immune modulation Immunomodulatory activity
Standard
60 amino acids
C305H448N88O91S8
Standard
Sequence
EAMHSFCAFKADDGPCRAAHPRWFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRD
Physicochemical Analysis
7059.88 Da
5.61
-2.03
-2.41
-0.0338
-0.71
0.62
-0.15
60.11
27.83
0.1500
6990.00
7365.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
2912.95
-29.75
106.0
99.0
232.0
492.0
14.0
64.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0276597 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Saccharomyces cerevisiae [Fungus]
Enzyme
9606;4932
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Disulfide-bonded therapeutic scaffold described in source text
Lipidation
Bio-Activity Profile
Immunomodulatory Coagulation factor replacement
Following subcutaneous administration of 30 mg ecallantide, the mean elimination half-life was 2.0 ± 0.5 hours [FDA Label].